

problems facing medicine require knowledge of the physics and chemistry of imaging techniques, health services and medical outcomes, and the limits of patient autonomy, to name but a few of the multitude of topics that impinge on medicine and the health care system with increasing urgency. The perspective of scholars working on such issues who also have medical education and clinical experience is as valuable as that of the physician trained in basic biomedical research.

The program at the University of Illinois is one of (unfortunately) only a few providing students with opportunities to seek M.D.-Ph.D.'s in such areas. Pursuing the two degrees separately is an option, but formal programs provide administrative, financial, and peer support that helps offset the challenges of seeking two advanced degrees.

Diane L. Gottheil

*Medical Humanities and Social Sciences
Program and
Medical Scholars Program,
College of Medicine,
University of Illinois,
Urbana, IL 61801*

Tony G. Waldrop

*Department of Physiology and
Medical Scholars Program,
College of Medicine,
University of Illinois,
Urbana, IL 61801*

Reference

1. H. M. Swartz and D. L. Gottheil, Eds., *The Education of Physician-Scholars* (Betz, Rockville, MD, 1993).

Medical schools award the M.D.-Ph.D. degree to brilliant, young "physician-researchers" who they hope will make a positive contribution to society by earning as much as doctors while having the same fun as scientists. No doubt some are great scientists, some are great physicians, and all have paid their dues. But it is beyond reason how the research and medical establishments (are they the same in this case?) can tolerate less than full dedication to careers which, under normal circumstances, individually require much more than a normal 40-hour-per-week commitment. No mere Ph.D. scientist would be hired for any faculty position if, during her interview, she stated she would like to help run her family business or take courses to "learn a way of learning," as Carl Nathan puts it, for an indeterminate amount of time every week. Yet the same department will not think twice about hiring someone who will do molecular genetics on Monday through Wednesday, see patients on Thursday through Saturday and, like God, rest on the seventh day.

To be an outstanding physician requires seeing lots of patients and reading everything written on your specialty. Likewise, to be an outstanding scientist requires performing lots of experiments and reading everything written on your specialty. No academic pedigree and no amount of genius can result in the 35-hour days or 53-day months required to practice enough medicine and science in a time frame usually associated with excellence in either field, much less both. As Nathan puts it, "You lose momentum and you're always behind in both." Amen.

Angelo DePalma

18 Hillside Avenue, Newton, NJ 07860

Conflict of Interest

Kenneth J. Rothman (Letters, 24 Sept., p. 1661) says that the review process should not be affected by considerations of conflict of interest. Daniel E. Koshland Jr. (Letters, 24 Sept., p. 1661) does not directly contradict this, but argues that the reader should be as informed as possible. The simple compromise is that the review process should ignore issues of conflict of interest, but that the publication process should not.

This simple distinction avoids ad hominem critiques of scientific articles while promoting rational skepticism in the reader. What's wrong with that?

Donald F. Klein

*Department of Psychiatry,
College of Physicians and Surgeons
of Columbia University,
New York, NY 10032*

Response: If all decisions were as simple as whether $2 + 2 = 4$ or 5 , we could ignore conflicts of interest; but unfortunately we have to make decisions about many less clear-cut cases involving interest, quality of data, newness, and so forth. Thus we like to know any reviewer's conflict (which is for our information only). We can then get additional reviewers while not discarding a possibly prejudiced source. For authors, the information of a conflict is needed by the reader only if the data are borderline or if the article is an opinion piece.

—**Daniel E. Koshland Jr.**

NIH: Intramural and Extramural Programs

In his article "Conflicting agendas shape NIH [the National Institutes of Health]" (Special News Report, 24 Sept., p. 1674) Jon Cohen quotes only part of my comments to him. What was quoted referred

to the NIH intramural program doing valuable research "that can't be done [as easily] on the outside." The pioneering work at NIH in gene therapy would be a good example.

One of my comments that was omitted was that if "research was ongoing in the extramural community, then similar work in the NIH intramural program must be of the highest caliber and at the cutting edge of the field." I think this statement could complement that of Igor Dawid, a developmental biologist at the National Institute of Child Health and Human Development, who is quoted as saying that, in the area he works in, "there aren't things that could only be done in the intramural program [at NIH]. . . ." Work similar to Dawid's in developmental biology can and is being done in the extramural community, but his work is obviously among the very best.

Carl Kupfer

*National Eye Institute,
National Institutes of Health,
Bethesda, MD 20892*

Japanese Superconducting Computer

In his article "Is the third time a charm for a superconducting computer?" (Research News, 24 Sept., p. 1670) Gary Taubes writes, "in 1991, [a] grandiose Japanese effort sponsored by the Ministry of International Trade and Industry came to a barren end" to explain the Japanese national program of research and development of Josephson integrated circuit technology that was conducted by the Agency of Industrial Science and Technology from 1981 until fiscal year 1989.

The aim of this program was to pursue two subjects: new parallel computer architecture and new devices made of gallium-arsenide field effect transistors, high electron mobility transistors, and Josephson tunnel junctions for high-speed computing systems for scientific and technological uses. The mission was to develop reliable integration technology, and it resulted in the invention of a fabrication process combining refractory superconducting materials such as niobium and niobium nitride as an alternative to the lead-alloy technology developed by IBM. Near the end of the program, in 1989, a superconducting prototype computer named ETL-JC1 was built in Tsukuba. To our knowledge, it was the first prototype superconducting computer to execute man-made computer programs installed in the Josephson ROM (read-only memory) chip with a Josephson central processing unit and RAM (random access memory) chips.

We therefore believe that the words "barren end" in Taubes' article do not quite fit the case.

Tsunenori Sakamoto
Director, Electron Devices Division,
Electrotechnical Laboratory,
1-1-4 Umezono, Tsukuba,
Ibaraki, 305, Japan

Saving Old-Growth Forests

I would like to clarify my comments regarding forests of eastern Oregon and Washington as quoted in the ScienceScope item "Can logging save old-growth forests" (1 Oct., p. 19). Health problems in these forests do not stem from too little logging, but rather from too much logging of the wrong kind, a situation that has been exacerbated by excluding natural wildfires. Some judicious and highly selective logging would probably benefit forest health in the short-run; however, the members of the Eastside Forests Scientific Society Panel, along with other scientists in this region, believe that a long-term solution lies not in more logging, but in restoring the forested landscape of the region to at least some reasonable approx-

imation of what it was before logging. Restoring the landscape of this region to one that is more resistant and resilient to natural disturbances is a critically important component of protecting the few remaining old-growth stands and old-growth associated species. Reducing tree stocking by logging some small trees and reintroducing the natural fire regime are ways to accomplish this while protecting and restoring the habitat and natural processes.

David A. Perry
Eastside Forests Scientific Society Panel, and
Department of Forest Sciences,
Oregon State University,
Corvallis, OR 97331-7501

Corrections and Clarifications

The ScienceScope item "NIH shakeup continues" (29 Oct., p. 643) incorrectly described the position of Francis Collins, director of the National Center for Human Genome Research, on the National Institutes of Health's (NIH's) decision 2 years ago to file for patents on gene fragments of unknown function. Collins does not believe it was appropriate for NIH to file for the patents in the first place, but since the applications have been filed, he now believes they should be pursued to a conclusion in order to clarify whether such gene fragments are patentable.

SAVE YOUR COPIES OF SCIENCE



CASES These custom-made, imprinted cases and binders are ideal for protecting your valuable Science copies from damage. Each binder or case holds one volume of Science, or 13 weekly issues

BINDER

or cases to hold a complete year of issues. Constructed from reinforced board and covered with durable, leather-like red material and stamped in gold, the cases are V-notched for easy access; binders have a special spring mechanism to hold individual rods which easily snap in.

Cases	1 - \$7.95	2 - \$14.95	4 - \$27.95
Binders	1 - \$9.95	2 - \$18.95	4 - \$35.95

SCIENCE

Jesse Jones Industries, Dept. SCE
499 East Erie Ave., Philadelphia, PA 19134

Enclosed is \$_____ for _____ Cases; Binders. Add \$1 per case/binder for postage & handling. Outside USA \$2.50 per case/binder (US funds only). PA residents add 7% sales tax.

Print Name _____

Address _____

No P.O. Box Numbers Please

City _____

State/Zip _____

CHARGE ORDERS (Minimum \$15): Am Ex, Visa, MC, DC accepted. Send card name, #, Exp. date.

CALL TOLL FREE 7 days, 24 hours 1-800-825-6690

— SATISFACTION GUARANTEED —

A new cGK Inhibitor: Rp-8-pCPT-cGMPS!

The R-isomer of 8- (4-chlorophenylthio) guanosine - 3', 5' - cyclic monophosphorothioate (Rp-8-pCPT-cGMPS) blocks the signal transduction of the "second messenger" cyclic GMP by inhibition of cGMP-dependent protein kinase (cGK) type I α . It is a novel and unique tool to prove a probable involvement of cyclic GMP in the biological system of interest. Developed by BIOLOG.

Outstanding properties:

- competitive inhibitor of cGMP-dependent protein kinase type I α , based on the widely accepted 8-pCPT-cGMP
- totally resistant against all known mammalian cyclic nucleotide - dependent phosphodiesterases
- excellent membrane permeability due to high lipophilicity
- good solubility in aqueous media

Detailed technical information available, Cat. No.: C 013.

BIOLOG - LIFE SCIENCE INSTITUTE -

Forschungslabor und Biochemica - Vertrieb GmbH

Head office:
Flughafenlandweg 9,
P.O. Box 10 71 25
D-28071 Bremen, Germany
Phone: 49 (0) 421 59 13 55
Fax: 49 (0) 421 59 47 71

US / Canada distributor:
Ruth Langhorst Int'l. Marketing
7514 Girard Ave. Suite 1-411
La Jolla, CA 92037
Phone: (619) 457-1573
Fax: (619) 456-0810

In Japan contact:
Wako Pure Chemical Ind., Ltd.
Phone:
Tokyo: 03-270-8571
Osaka: 06-203-3741

Circle No. 10 on Readers' Service Card

CUSTOM DNA SYNTHESIS

PURE & SIMPLE

(and now more economical than ever)

☐ PRICE \$ **2.50**
+ per base plus setup

- ☐ SUPERB TECHNICAL SUPPORT
+
☐ IMPECCABLE QUALITY
+
☐ WORLD'S FASTEST SERVICE

MIDLAND

THE UNDISPUTED #1
CUSTOM DNA SYNTHESIS SERVICE

THE MIDLAND CERTIFIED REAGENT COMPANY
3112-A WEST CUTHBERT AVENUE
MIDLAND, TEXAS, 79701

PHONE 1-800-247-8766 FAX 1-915-694-2387

Circle No. 4 on Readers' Service Card